Clinical Trial Update: Study of Anlotinib in Patients With Medullary Thyroid Carcinoma(ALTER01031) [Phase 2, Phase 3]

View source ↗

Summary

A study evaluating anlotinib in medullary thyroid carcinoma has completed Phase 2 and Phase 3 trials.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Medullary Thyroid Carcinoma

Drugs mentioned

• Anlotinib (anlotinib)

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: Medullary Thyroid Carcinoma | Phase 2, Phase 3 | Status: COMPLETED